Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.

@article{Mascelli2000TherapeuticHC,
  title={Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.},
  author={Mary Ann Mascelli and Neal S. Kleiman and Stanley J. Marciniak and Lakshmi V. Damaraju and Harlan F. Weisman and Robert E. Jordan},
  journal={American heart journal},
  year={2000},
  volume={139 4},
  pages={
          696-703
        }
}
BACKGROUND This study evaluated the effect of heparin on the platelet reactivity and the pharmacodynamic profile of abciximab. METHODS AND RESULTS Ex vivo studies were performed on patients undergoing elective percutaneous coronary intervention (n = 26) who were at moderate to high risk of ischemic complications. Patients received a 12,000-U bolus of heparin followed by a 0.25-mg/kg bolus of abciximab. Before abciximab treatment, platelet aggregation responses to a variety of stimuli were… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS